Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Finasteride Stories

2010-08-10 23:00:17

Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The first results of the PCPT were published in 2003 in The New England Journal of Medicine and were widely reported. The...

2010-07-12 15:15:00

NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract (SPE), SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia (BPH). BPH, also known as an enlarged prostate, is the most common benign proliferative disorder in men, affecting more than 50 percent of men over the age of 70. Symptoms...

2010-04-01 09:04:26

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine. The four-year study found that dutasteride (Avodart®) significantly reduced the chances that men would be diagnosed with the tumors that are most often treated excessively: those that...

2010-01-12 07:15:00

NEW YORK, Jan. 12 /PRNewswire/ -- HairLossSpecialists.com is pleased to announce the latest addition to its national network of hair-restoration experts: Dr. Mark DiStefano, a highly experienced hair transplant surgeon on the East Coast. With state-of-the-art hair restoration clinics in New York, Massachusetts, Connecticut, New Hampshire and Rhode Island, Dr. DiStefano can conveniently treat hair-loss patients throughout the Tri-State area and beyond. His full spectrum of hair-restoration...

2009-11-20 08:52:00

PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-USNewswire/ -- In response to a recent New York Times article that questions why currently available medications designed to treat and prevent some cancers are being ignored, ECRI Institute, an independent nonprofit organization, is offering a roadmap to the evidence on Finasteride for Prevention of Prostate Cancer for free download. The November 13, 2009, New York Times article, "Drugs to Deter Some Cancers Are Not Taken," was the most e-mailed...

2009-07-29 13:00:00

DERMATOLOGISTS CAN HELP WOMEN GET TO THE ROOT OF HAIR LOSS BOSTON, July 29 /PRNewswire-USNewswire/ -- For many women, their hair is one of their most defining characteristics. From short and sassy bobs to long, cascading curls, the right hairstyle can make any woman look more pulled together and can even take years off of her appearance. That's why hair loss can be particularly devastating for women, and dermatologists advise that it should be addressed at the first noticeable signs of a...

2009-07-13 07:37:37

Current research is inconclusive regarding the relationship between alcohol consumption and prostate cancer risk. Researchers led by Zhihong Gong Ph.D. of the University of California San Francisco, examined the associations of total alcohol, type of alcoholic beverage, and drinking pattern with risks of total, low- and high-grade prostate cancer. They used data from more than 10,000 men participating in the Prostate Cancer Prevention Trial (PCPT). They found participants who reported heavy...

2009-07-08 07:19:47

For the last six years, doctors have faced a dilemma about whether to treat men at risk of prostate cancer with the drug finasteride. On one hand, the drug had been shown to prevent cancer in about one of every four patients who received it. On the other, those who did develop cancer while on the drug were 25 percent more likely to have a more aggressive form of the disease.Now new research from Stanford University School of Medicine appears to show that the drug did not cause those more...

2009-05-06 06:30:00

SEATTLE, May 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2009. Revenue for the first quarter of 2009 was $30,000 compared to $31,000 for the quarter ended March 31, 2008. Dendreon's total operating expenses for the three months ended March 31, 2009 were $17.0 million compared to $19.2 million for the same period in 2008. The net loss for the quarter ended March 31, 2009 was $15.4 million, or $0.16 per share...

2009-04-28 10:30:00

-- Data Presented at American Urological Association Annual Meeting -- SEATTLE and CHICAGO, April 28 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets TRPM8 (a transmembrane cation channel protein), to treat benign prostatic hyperplasia (BPH). D-3263 demonstrated the ability to reduce BPH alone and in combination with finasteride,...